Porton Pharma Solutions Ltd.

SZSE:300363 Stock Report

Market Cap: CN¥8.2b

Porton Pharma Solutions Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Nianfeng Ju

Chief executive officer

CN¥1.6m

Total compensation

CEO salary percentagen/a
CEO tenure15.5yrs
CEO ownership10.9%
Management average tenure3.1yrs
Board average tenure3.4yrs

Recent management updates

Recent updates

Pinning Down Porton Pharma Solutions Ltd.'s (SZSE:300363) P/S Is Difficult Right Now

Mar 19
Pinning Down Porton Pharma Solutions Ltd.'s (SZSE:300363) P/S Is Difficult Right Now

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Jan 01
Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Revenues Not Telling The Story For Porton Pharma Solutions Ltd. (SZSE:300363) After Shares Rise 31%

Nov 14
Revenues Not Telling The Story For Porton Pharma Solutions Ltd. (SZSE:300363) After Shares Rise 31%

Porton Pharma Solutions Ltd.'s (SZSE:300363) 39% Price Boost Is Out Of Tune With Revenues

Sep 30
Porton Pharma Solutions Ltd.'s (SZSE:300363) 39% Price Boost Is Out Of Tune With Revenues

Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?

Sep 25
Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Jun 26
Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically

May 02
Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically

Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Mar 26
Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Mar 04
Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

CEO

Nianfeng Ju (52 yo)

15.5yrs

Tenure

CN¥1,634,900

Compensation

Mr. Nianfeng Ju serves as General Manager of Porton Imp & Exp Ltd. Nianfeng Ju served as the General Manager of Porton Co., Ltd. He serves as a General Manager of Porton Pharma Solutions Ltd.and serves as...

Leadership Team

NamePositionTenureCompensationOwnership
Nianfeng Ju
Chairman & GMno dataCN¥1.63m10.86%
CN¥ 892.2m
Hui Chen
Deputy GM & CFO3.1yrsCN¥1.39m0.0055%
CN¥ 454.2k
Yinchun Bai
Senior Deputy GM & COO3.1yrsCN¥1.87m0.029%
CN¥ 2.4m
Wei Pi
Deputy GM & Secretary of the Board of Directors3.1yrsCN¥879.10k0.016%
CN¥ 1.3m
Po Zhu
Deputy General Manager3.1yrsCN¥1.02m0.049%
CN¥ 4.1m
Qi Chen
Deputy General Manager1.8yrsCN¥1.45mno data

3.1yrs

Average Tenure

49yo

Average Age

Experienced Management: 300363's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Nianfeng Ju
Chairman & GM15.5yrsCN¥1.63m10.86%
CN¥ 892.2m
Weiqiang Yang
Non Independent Director3.8yrsCN¥180.00kno data
Guohua Cao
Independent Director4.7yrsCN¥180.00kno data
Hui Zeng
Employee Representative Supervisor12.6yrsCN¥212.80kno data
Lin Yuan
Independent Director3.1yrsCN¥180.00kno data
Jinwei Pang
Independent Director3.1yrsCN¥180.00kno data
Yongqing Tan
Non-Employee Chairman of the Supervisory Board6.1yrsno datano data
Ying Xue
Non-Independent Director4.7yrsCN¥180.00k0.0027%
CN¥ 222.6k
Lina Hu
Non-Independent Director3.1yrsCN¥180.00kno data
Guojun Cao
Non-Independent Director3.1yrsCN¥180.00kno data
Yuchen Wu
Non-Employee Supervisor3.1yrsno datano data
Ke Li
Non-Independent Directorless than a yearno datano data

3.4yrs

Average Tenure

57yo

Average Age

Experienced Board: 300363's board of directors are considered experienced (3.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/16 12:06
End of Day Share Price 2025/05/16 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Porton Pharma Solutions Ltd. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jin ZhangChina International Capital Corporation Limited
Zhu ChenCitic Securities Co., Ltd.
Kai WangCitic Securities Co., Ltd.